BioNTech Shrugs Off Colorectal Setback as Seoul Lung Cancer Readouts Take Centre Stage
Published on 09/02/2026 at 22:31 | Editorial boerse-global.de
The arithmetic of biotech investing rarely stays static for long, and BioNTech's recent trading pattern is a case in point. Shares in the Mainz-based company have clawed back 2.3 percent to €89.40 since Monday's abrupt termination of a Phase 2 colorectal cancer trial — a recovery that suggests investors have already recalibrated their expectations around a different part of the pipeline entirely.
That recalibration is understandable given what sits on the horizon. Between September 12 and 15, BioNTech will present fresh clinical data at the International Association for the Study of Lung Cancer's world congress in Seoul, with a late-breaking presentation focused on combining pumitamig — developed alongside Bristol Myers Squibb — with the B7H3-directed antibody-drug conjugate elfetabart drozuntecan, a partnership with Duality Biologics. The company bills this as the first available combination dataset for a PD-(L)1xVEGF bispecific immunotherapy paired with an ADC in lung cancer treatment.
The market's willingness to move past the colorectal disappointment is also visible in the charts. Since Guido Oelkers was named incoming CEO roughly a month ago, the stock has gained 11.8 percent, and it has risen 13.2 percent since second-quarter earnings landed. The current price sits 7.1 percent above its 50-day moving average, though it remains about 16 percent below January's 52-week high of €105.80. At the other end of the range, the shares trade more than 31 percent above the early-March trough of €68.35.
A Pipeline Pivot From Gut to Lung
The halted trial involved autogene cevumeran in ctDNA-positive, resected colorectal cancer. An independent data and safety monitoring board flagged a numerical imbalance in overall survival and concluded that continuing would be unlikely to alter the efficacy outcome, prompting BioNTech to pull the plug. The setback stings, but it targets a different mechanism than the company's core oncology thrust — and the lung cancer franchise is considerably broader, spanning multiple drug candidates across different modalities.
Should investors sell immediately? Or is it worth buying BioNTech?
Earlier this year, BioNTech delivered interim results from the Phase 2 ROSETTA Lung-02 study showing encouraging response rates in first-line non-small cell lung cancer across varying PD-L1 expression levels. In March, data from stage one of the global Phase 3 PRESERVE-003 trial for gotistobart demonstrated clinically meaningful survival benefits and antitumour activity versus the previous standard of care in later-line squamous non-small cell lung cancer. Seoul will bring updated survival figures for gotistobart as well as mRNA-based immunotherapy approaches.
The most striking data point, however, emerged back in May at the ASCO annual meeting. There, BioNTech presented Phase 2 interim results showing pumitamig combined with chemotherapy achieved confirmed response rates of up to 72.7 percent in advanced non-small cell lung cancer, with a disease control rate of 100 percent. UBS responded by upgrading the stock from Neutral to Buy with a $135 price target. The question now is whether the Seoul dataset can build on that momentum.
Balance Sheet Provides the Backstop
None of this research firepower would be possible without considerable financial firepower. BioNTech ended the second quarter with €16.6 billion in cash and securities, enabling it to maintain 14 ongoing pivotal studies even as COVID-19 revenues dwindle. The second-quarter numbers themselves were sobering — revenue collapsed 59 percent to €105.6 million and the net loss widened to €820.8 million, prompting the company to trim full-year guidance to between €1.6 billion and €1.9 billion. A share buyback programme of up to $1 billion is also underway.
The market's muted reaction to those weak figures — and its resilience after the trial halt — speaks to a broader narrative: investors are looking past the vaccine franchise's decline and focusing on oncology's late-stage potential. The current market capitalisation stands at €22.04 billion.
Analyst Caution Lingers Beneath the Surface
Not everyone has abandoned a degree of wariness. Canaccord Genuity trimmed its price target to $136 from $142 in late August following the trial termination, while Morgan Stanley had already reduced its target from $126 to $119 in early August — before the halt — while maintaining an Overweight rating. These adjustments suggest expectations are being tempered rather than abandoned.
The stock's 71 percent volatility over the past year cuts both ways: Seoul could deliver the positive catalyst that validates the recent recovery, or it could expose the gap between expectation and reality. Oelkers' appointment, effective no later than February 1, 2027, signals strategic continuity for the longer term, but the immediate catalyst is geographic rather than managerial. The next meaningful price move for BioNTech will be determined not in Mainz, but in South Korea.
Ad
BioNTech Stock: New Analysis - 2 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
